Skip to main content
    R

    Rein Therapeutics Inc (RNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.55
    -0.01 (-1.41%)

    Market Cap: $47.63M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Rein Therapeutics Inc (RNTX) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Rein Therapeutics (RNTX) is expected to report earnings on Mar 24, 2027. In the quarter ended Jun 30, 2026, Rein Therapeutics reported EPS of -$0.10, above the -$0.27 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    44%(15/34)
    Avg Surprise
    -41.83%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.15 - -$0.11
    4 analysts
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    RNTX has an expected report date of Mar 24, 2027.

    Earnings History

    Of the 34 quarters below that had an estimate, RNTX beat 15, missed 17 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 862.50% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$0.10-$0.27-$0.27 - -$0.07+62.96%BeatN/A21 up, 0 downAug 14, 2026
    Mar 31, 2026-$0.19-$0.49-$0.49 - -$0.49+61.22%BeatN/A10 up, 0 downMay 15, 2026
    Dec 31, 2025-$1.22-$0.22-$0.24 - -$0.19-467.44%MissN/A2N/AMar 26, 2026
    Sep 30, 2025-$0.21-$0.24-$0.26 - -$0.22+12.50%BeatN/A20 up, 0 downNov 14, 2025
    Jun 30, 2025-$0.28-$0.22N/A-27.27%MissN/AN/AN/AAug 14, 2025
    Mar 31, 2025-$0.25-$0.21N/A-19.05%MissN/AN/A0 up, 0 downApr 7, 2025
    Dec 31, 2024-$0.26-$0.48-$0.48 - -$0.48+45.56%BeatN/A10 up, 0 downDec 31, 2024
    Sep 30, 2024-$0.27-$0.35N/A+22.86%BeatN/AN/AN/ANov 14, 2024
    Jun 30, 2024-$0.45-$0.42N/A-7.14%MissN/AN/AN/AAug 14, 2024
    Mar 31, 2024-$0.86-$1.02N/A+15.69%BeatN/AN/AN/AMay 15, 2024
    Dec 31, 2023-$1.54-$0.16N/A-862.50%MissN/AN/AN/ADec 31, 2023
    Sep 30, 2023-$0.40-$0.20N/A-100.00%MissN/AN/AN/AOct 13, 2023
    Jun 30, 2023-$0.39N/AN/AN/AN/AN/AN/AN/AAug 8, 2023
    Mar 31, 2023-$1.05-$0.60N/A-75.00%MissN/AN/AN/AMay 8, 2023
    Dec 31, 2022-$1.00-$1.34N/A+25.37%BeatN/AN/AN/AMar 20, 2023
    Sep 30, 2022-$1.40-$1.60N/A+12.50%BeatN/AN/AN/ANov 1, 2022
    Jun 30, 2022-$1.80-$1.90N/A+5.26%BeatN/AN/AN/AAug 15, 2022
    Mar 31, 2022-$1.80-$1.60N/A-12.50%MissN/AN/AN/AMay 5, 2022
    Dec 31, 2021-$0.08-$0.08N/A0.00%In lineN/AN/AN/AMar 28, 2022
    Sep 30, 2021-$1.40-$1.40N/A0.00%In lineN/AN/AN/ANov 12, 2021
    Jun 30, 2021-$1.20-$1.40N/A+14.29%BeatN/AN/AN/AAug 11, 2021
    Mar 31, 2021-$1.60-$1.10N/A-45.45%MissN/AN/AN/AMay 11, 2021
    Dec 31, 2020-$0.12-$0.13N/A+5.81%BeatN/AN/AN/AMar 24, 2021
    Sep 30, 2020-$2.60-$2.75N/A+5.45%BeatN/AN/AN/ANov 12, 2020
    Jun 30, 2020-$2.80-$3.73N/A+24.93%BeatN/AN/AN/AAug 5, 2020
    Mar 31, 2020-$4.80-$4.20N/A-14.29%MissN/AN/AN/AMay 11, 2020
    Dec 31, 2019-$0.26-$0.27N/A+3.70%BeatN/AN/AN/AMar 30, 2020
    Sep 30, 2019-$5.60-$4.75N/A-17.89%MissN/AN/AN/ANov 7, 2019
    Jun 30, 2019-$5.20-$4.45N/A-16.85%MissN/AN/AN/AAug 6, 2019
    Mar 31, 2019-$9.80-$7.75N/A-26.45%MissN/AN/AN/AMay 8, 2019
    Sep 30, 2018-$10.00-$11.10N/A+9.91%BeatN/AN/AN/ANov 7, 2018
    Jun 30, 2018-$12.80-$10.40N/A-23.08%MissN/AN/AN/AAug 7, 2018
    Mar 31, 2018-$10.40-$10.00N/A-4.00%MissN/AN/AN/AMay 9, 2018
    Sep 30, 2017-$9.00-$6.90N/A-30.43%MissN/AN/AN/ANov 9, 2017
    Jun 30, 2017-$8.27-$8.20N/A-0.85%MissN/AN/AN/AAug 10, 2017
    Last 35 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.96, after -$1.84 the year before. It was -$71.33 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.96N/A
    Dec 31, 2024-$1.84N/A
    Dec 31, 2023-$3.38N/A
    Dec 31, 2022-$6.00N/A
    Dec 31, 2021-$4.28N/A
    Dec 31, 2020-$10.32N/A
    Dec 31, 2019-$71.33N/A

    Frequently Asked Questions About RNTX

    When is Rein Therapeutics's next earnings date?

    Rein Therapeutics's next earnings report is expected for Mar 24, 2027.

    Did RNTX beat earnings estimates last quarter?

    Yes. Rein Therapeutics reported EPS of -$0.10 for the quarter ended Jun 30, 2026, above the -$0.27 estimate, a 62.96% surprise.

    What EPS do analysts expect from RNTX next quarter?

    The consensus EPS estimate for Rein Therapeutics for the quarter ending Dec 31, 2026 is -$0.13 from 4 analysts, with estimates from -$0.15 to -$0.11.

    How often does RNTX beat earnings estimates?

    Rein Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -38.58%.